Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1987 1
1988 1
1992 1
2002 2
2005 2
2007 2
2008 1
2009 1
2010 1
2011 1
2013 4
2014 4
2015 6
2016 4
2017 9
2018 6
2019 13
2020 10
2021 16
2022 20
2023 12
2024 19
2025 17
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.
Hulscher N, Victory K, Thorp JA, Pinsky D, Diaz-Villalobos A, Gillooly P, Coulson F, Annazone M, Radesi C, Brooks J, McCULLOUGH PA, Risch H. Hulscher N, et al. Anticancer Res. 2026 Jun;46(6):3243-3255. doi: 10.21873/anticanres.18194. Anticancer Res. 2026. PMID: 42203321
BACKGROUND/AIM: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole demonstrate multi-target anticancer activity in preclinical models. This study evaluates real-world patient-reported outcomes, safety, …
BACKGROUND/AIM: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazol …
Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment.
Al-Zoubi RM, Farhan A, Hanbali B, Al-Zoubi SR, Khan A, Shkoor M, Bani-Yaseen AD, Al Zoubi MS, Agouni A. Al-Zoubi RM, et al. Eur J Med Chem. 2026 May 25;316:118987. doi: 10.1016/j.ejmech.2026.118987. Online ahead of print. Eur J Med Chem. 2026. PMID: 42217373 Free article. Review.
Drugs originally developed to treat parasitic infections, including ivermectin, mebendazole, niclosamide, albendazole, artesunate, flubendazole, and other antiparasitic agents, have demonstrated compelling anticancer properties across a wide range of preclinical models. Th …
Drugs originally developed to treat parasitic infections, including ivermectin, mebendazole, niclosamide, albendazole, artesunate, fl …
Mebendazole impairs the expression and function of enzymes in nucleotide metabolism pathways, leading to Selective Cytotoxicity, Cell Cycle Arrest, and Damage to Cell Morphology in Gastric Cancer.
da Silva EL, Pantoja Mesquita F, da Rocha Lima PV, de Araújo Filho JH, de Oliveira FL, da Lima AB, Noronha Souza PF, Montenegro RC. da Silva EL, et al. Chem Biol Interact. 2026 May 1;430:111973. doi: 10.1016/j.cbi.2026.111973. Epub 2026 Feb 18. Chem Biol Interact. 2026. PMID: 41720422 Free article.
The nucleotide biosynthetic pathway is essential for tumor replication through DNA and RNA synthesis, making it a critical target for cancer therapies. Mebendazole (MBZ) has shown promise in inhibiting cell proliferation and glucose metabolism in gastric cancer …
The nucleotide biosynthetic pathway is essential for tumor replication through DNA and RNA synthesis, making it a critical target for can …
Management of advanced HR-positive breast cancer using metabolically supported chemotherapy and repurposed drugs: a case report.
Slocum AK, Tastekin D, Duraj T, Seyfried TN. Slocum AK, et al. Front Oncol. 2026 Apr 22;16:1795402. doi: 10.3389/fonc.2026.1795402. eCollection 2026. Front Oncol. 2026. PMID: 42100430 Free PMC article.
INTRODUCTION: Metastatic hormone receptor-positive (HR+) breast cancer is largely incurable once resistance to conventional treatments occurs. Emerging evidence suggests that progression free and overall survival can improve by targeting the distinct metabolic phenotype of …
INTRODUCTION: Metastatic hormone receptor-positive (HR+) breast cancer is largely incurable once resistance to conventional treatment …
Mebendazole Attenuates Cellular Invasion in a 3D Culture Model of Meningioma by Disrupting Rho-GTPase-Mediated Microtubule Function.
James MM, Clara Elena LV, Agadha W, Chuen CAH, Lee GC. James MM, et al. Oncol Res. 2026 Apr 22;34(5):21. doi: 10.32604/or.2026.074958. eCollection 2026. Oncol Res. 2026. PMID: 42065056 Free PMC article.
Invasion into the brain is a diagnostic feature of grade II meningiomas and is associated with recurrence and poor prognosis. Mebendazole is a microtubule inhibitor typically prescribed as an anthelmintic. However, it has the potential to be repurposed for cancer tr …
Invasion into the brain is a diagnostic feature of grade II meningiomas and is associated with recurrence and poor prognosis. Mebendazole …
USP5 regulates purine metabolism and represents a therapeutic target in esophageal cancer.
Zhao K, Zhang L, Yan M, Fang S, Wang Z, Song Y, Liu M, Zhang C, Shao Y, Jia X, Guo Q, Guo M, Yin J, Jin G, Dong Z. Zhao K, et al. Cell Death Dis. 2026 Apr 1;17(1):439. doi: 10.1038/s41419-026-08683-4. Cell Death Dis. 2026. PMID: 41922317 Free PMC article.
Ubiquitination is a critical regulator of cancer development, yet the role of deubiquitinases in purine metabolism remains largely unexplored. ...Guanine supplementation enhanced ESCC cell proliferation, whereas dietary purine restriction suppressed tumor progression in vi …
Ubiquitination is a critical regulator of cancer development, yet the role of deubiquitinases in purine metabolism remains largely un …
Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A.
Aqel RS, Ismail AS, El-Tanani M, Satyam SM. Aqel RS, et al. PLoS One. 2026 Mar 26;21(3):e0345701. doi: 10.1371/journal.pone.0345701. eCollection 2026. PLoS One. 2026. PMID: 41886499 Free PMC article.
BACKGROUND: Cancer progression involves coordinated regulation of oncogenes and tumor suppressors. ...Collectively, these findings reveal cell-type-specific modulation of oncogenic and suppressor pathways. CONCLUSION: This multi-cancer investigation identifies ENOX2 …
BACKGROUND: Cancer progression involves coordinated regulation of oncogenes and tumor suppressors. ...Collectively, these findings re …
Inhibition of Antioxidant Genes Expression in Echinococcus Granulosus by Baicalein: Implications for Novel Antiparasitic Strategies.
Al-Aredhi HS. Al-Aredhi HS. Acta Parasitol. 2026 Feb 11;71(1):35. doi: 10.1007/s11686-026-01217-0. Acta Parasitol. 2026. PMID: 41670898
BACKGROUND: Drug treatment of hydatid cysts is usually carried out using benzimidazole compounds such as albendazole and mebendazole. However, limited efficacy, the need for long-term use, and side effects such as liver damage and gastrointestinal problems have made the us …
BACKGROUND: Drug treatment of hydatid cysts is usually carried out using benzimidazole compounds such as albendazole and mebendazole. …
Mebendazole inhibits PELI3-mediated ubiquitination of TRADD in non-small cell lung cancer cells.
Li F, Li X, Li H, Li S, Liu Y, Bai X, Qi T, Zhao X, He Y. Li F, et al. Front Oncol. 2026 Jan 9;15:1728170. doi: 10.3389/fonc.2025.1728170. eCollection 2025. Front Oncol. 2026. PMID: 41584581 Free PMC article.
CCK-8 assay was performed in A549 and HCC827 cells incubated with increasing doses of Mebendazole. The expression of TRADD and PELI3 after Mebendazole incubation was assayed with Western Blot and RT-PCR. ...CONCLUSIONS: PELI3 can function as an E3 ubiquitin ligase t …
CCK-8 assay was performed in A549 and HCC827 cells incubated with increasing doses of Mebendazole. The expression of TRADD and PELI3 …
Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model.
Mansoori S, Blom K, Andersson C, Fryknäs M, Larsson R, Nygren P. Mansoori S, et al. Oncol Rep. 2026 Jan;55(1):9. doi: 10.3892/or.2025.9014. Epub 2025 Nov 7. Oncol Rep. 2026. PMID: 41201043 Free PMC article.
Mebendazole (Mbz), a well-known anthelminthic drug, has demonstrated anticancer properties in tumor models and patients, and is thus under consideration for repositioning into an anticancer drug. ...In the present study, the anticancer effects of Mbz, alone and in combinat …
Mebendazole (Mbz), a well-known anthelminthic drug, has demonstrated anticancer properties in tumor models and patients, and is thus …
146 results